Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced CEO John P. Butler will participate in a fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced CEO John P. Butler will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. This virtual event will provide insights about the company’s mission and ongoing developments. A recorded version of the presentation will be available on the company’s investor website starting March 9. Akebia, founded in 2007 and based in Cambridge, Massachusetts, aims to improve the lives of those affected by kidney disease.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer of Akebia, will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, which takes place virtually March 9-10, 2021.
The recorded presentation will be available on the Investors section of the Company's website at https://ir.akebia.com beginning Tuesday, March 9.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-hc-wainwright-global-life-sciences-conference-301237797.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.